HC Wainwright & Co. Reiterates Buy on ACADIA Pharmaceuticals, Maintains $28 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and maintained a $28 price target.
June 14, 2023 | 10:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on ACADIA Pharmaceuticals and maintained a $28 price target.
The reiteration of a Buy rating and maintenance of a $28 price target by HC Wainwright & Co. analyst Andrew Fein indicates a positive outlook for ACADIA Pharmaceuticals. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100